Medicon Valley Biomedical Newsletter

Active Biotech AB and MediGene AG have announced the initiation of a clinical Phase IIa trial of the drug candidate RhuDex for the treatment of rheumatoid arthritis. The placebo-controlled tria...

ALK-Abelló A/S has launched GRAZAX, the world's first tablet-based vaccine against grass pollen allergy, in Sweden. GRAZAX is the first allergy tablet that treats the underlying cause of grass pol...

Astion Pharma A/S has raised EUR 5 million in new capital from its existing shareholders. The new capital will be used to fund its clinical projects and two late-stage preclinical development candidat...

BioGaia AB has signed a distribution agreement with Delta Medical Promotions AG, giving Delta Medical exclusive rights to distribute BioGaia's probiotic drops in Ukraine and non-exclusive rights i...

BioInvent International AB and ThromboGenics NV have announced that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402...

Bonesupport AB, which develops synthetic, injectable ceramic bone substitute, has signed its first commercial distribution agreement in North America. The agreement with the American company, Signus M...

Danish researchers from Biotech Research & Innovation Centre, BRIC, at University of Copenhagen have identified a new group of proteins that regulate the growth and differentiation of stem cells. ...

Camurus AB has received approval to begin a Phase II proof-of-concept clinical trial of CAM2028 for the treatment of pain in oral mucositis. The multicenter trial will be conducted in the EU and enrol...

Private equity fund, EQT V, has signed a definitive agreement to acquire 100% of Dako A/S. The total consideration for the transaction is EUR 1 billion. Dako is currently owned by the Harboe family, 6...

Genmab A/S has announced that the worldwide agreement to co-develop and commercialise HuMax-CD20, ofatumumab, entered into between Genmab and GlaxoSmithKline has received antitrust clearance from the ...

Ludesi AB has signed a contract with Basel's DSM Nutritional Products. Under the agreement, DSM will use Ludesi's image analysis of two-dimensional, 2D, protein gels. After testing the image a...

Lund University, Novartis, and The Broad Institute, a joint venture between Massachusetts Institute of Technology and Harvard University, have announced the completion of a genome-wide map of genetic ...

MediCult A/S has obtained FDA 510 k clearance of the product EmbryoAssist for the US market. EmbryoAssist is a new enriched culture medium for the day 2/3 transfers, which is the most commo...

Novo Nordisk A/S and TransTech Pharma have announced an agreement whereby TransTech has obtained an exclusive licence from Novo Nordisk to its clinical glucokinase activator, GKA, programme. Tests in ...

Novo Nordisk A/S and the Chinese Academy of Science have signed an agreement that establishes a joint research foundation in China. The aim of Novo Nordisk-Chinese Academy of Science Research Foundati...

Novozymes A/S is establishing its first R&D operations in India. It is building new lab and office facilities in Bangalore which will be completed in mid-2008 and will house between 50 and 60 empl...

Symphogen has announced that it has raised EUR 5 million from the Dutch venture capital fund Gilde Healthcare Partners. This investment is an addition to Symphogen's last financing round and bring...

UpFront Chromatography A/S has announced collaboration with Solanic for the installation of a Rhobust industrial production plant for the extraction of high-quality functional proteins from the side-s...

Vivolution A/S has announced that the French venture company Seventure and the Danish venture fund Vecata inject EUR 7.5 million in the company. The company has two products based on the same t...